Chart Industries (NYSE:GTLS – Get Free Report) updated its FY25 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $12.00-13.00 for the period, compared to the consensus estimate of $12.60. The company issued revenue guidance of $4.65-4.85 billion, compared to the consensus revenue estimate of $4.85 billion. Chart Industries also updated its FY 2024 guidance to 9.000-9.000 EPS.
Chart Industries Stock Up 6.2 %
Shares of GTLS traded up $8.08 on Monday, reaching $138.08. The stock had a trading volume of 946,568 shares, compared to its average volume of 625,528. The company has a debt-to-equity ratio of 1.28, a quick ratio of 0.98 and a current ratio of 1.27. Chart Industries has a 12-month low of $101.60 and a 12-month high of $171.68. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 39.68, a price-to-earnings-growth ratio of 0.56 and a beta of 1.71. The company has a 50-day simple moving average of $121.62 and a 200-day simple moving average of $136.98.
Chart Industries (NYSE:GTLS – Get Free Report) last released its earnings results on Friday, November 1st. The industrial products company reported $2.18 earnings per share for the quarter, missing analysts’ consensus estimates of $2.56 by ($0.38). Chart Industries had a return on equity of 12.27% and a net margin of 2.80%. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the company earned $1.28 earnings per share. The firm’s quarterly revenue was up 18.3% compared to the same quarter last year. Sell-side analysts predict that Chart Industries will post 9.94 EPS for the current year.
Analyst Ratings Changes
View Our Latest Analysis on Chart Industries
Insider Buying and Selling at Chart Industries
In other news, Director Linda S. Harty purchased 5,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $48.05 per share, for a total transaction of $240,250.00. Following the completion of the purchase, the director now owns 5,000 shares in the company, valued at approximately $240,250. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Jillian C. Evanko bought 440 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were bought at an average price of $114.31 per share, for a total transaction of $50,296.40. Following the completion of the purchase, the chief executive officer now directly owns 125,448 shares of the company’s stock, valued at approximately $14,339,960.88. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Linda S. Harty bought 5,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was bought at an average price of $48.05 per share, for a total transaction of $240,250.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at $240,250. The disclosure for this purchase can be found here. Insiders purchased a total of 7,152 shares of company stock valued at $482,278 in the last three months. Company insiders own 0.95% of the company’s stock.
Chart Industries Company Profile
Chart Industries, Inc engages in the designing, engineering, and manufacturing of process technologies and equipment for the gas and liquid molecules in the United States and internationally. The company operates in four segments: Cryo Tank Solutions, Heat Transfer Systems, Specialty Products, and Repair, Service & Leasing.
See Also
- Five stocks we like better than Chart Industries
- P/E Ratio Calculation: How to Assess Stocks
- Intel: Is Now the Time to Be Brave?Â
- How to Calculate Stock Profit
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Health Care Stocks Explained: Why You Might Want to Invest
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Chart Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chart Industries and related companies with MarketBeat.com's FREE daily email newsletter.